Literature DB >> 16269053

Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient.

Rubén E Quirós-Tejeira1, I-Fen Chang, Lisa J Bristow, Saul J Karpen, John A Goss.   

Abstract

The toxicities associated with the chronic use of tacrolimus are well described in the literature; however, little is known about the management during an acute overdose. Phenobarbital is a long-acting barbiturate metabolized in the liver by the cytochrome p450 3a4 system. It is known to enhance the rate of metabolism of itself and the clearance of drugs metabolized by p450 3a4. Because tacrolimus is a substrate of this particular isoenzyme, phenobarbital can be considered a potential option when rapid decreases in tacrolimus whole-blood levels are desired. We hereby report our experience using intravenous phenobarbital in the management of two infants with acute elevations in their tacrolimus whole-blood concentration following liver transplantation. Phenobarbital, through its up-regulation of hepatic cytochrome p450 system increases the elimination of whole-blood tacrolimus concentration in acute overdose situations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269053     DOI: 10.1111/j.1399-3046.2005.00368.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Red cell exchange transfusion as a rescue therapy for tacrolimus toxicity in a paediatric renal transplant.

Authors:  Hugh McCarthy; Carol Inward; Steve Marriage; Peter Astley; E Jane Tizard
Journal:  Pediatr Nephrol       Date:  2011-09-07       Impact factor: 3.714

2.  Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients.

Authors:  Arin S Jantz; Samir J Patel; Wadi N Suki; Richard J Knight; Arvind Bhimaraj; A Osama Gaber
Journal:  Case Rep Transplant       Date:  2013-06-13

3.  Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis.

Authors:  Aditi Sharma; Krista A Wahby; Mohammed Inany; Sarah J Lee
Journal:  BMJ Case Rep       Date:  2020-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.